Achieving the capacity to detect minimal numbers of neoplastic cells is a major cancer diagnostic challenge. Chromosomal translocations such as the t(14;18)-(q32;q21) found in follicular and some nonfollicular lymphomas provide a tumor-specific molecular marker. The 14;18 breakpoints are focused at one of six immunoglobulin heavy chain joining (JH) regions on chromosome 14 and a small major breakpoint region (MBR) of the BCL2 gene on chromosome 18. We utilized universal oligonucleotide primers of a region 5' to the BCL2 MBR and at the 3' end of JH segments to initiate a DNA polymerase chain reaction that amplified these BCL2-JH junctures. Use of thermostable DNA polymerase enabled annealing and synthesis steps at temperatures approaching the melting point of the primers, providing a sensitive and specific assay capable of detecting 1 lymphoma cell in 106 normal cells. This technique identified the subclinical presence of leukemic cells in all seven patients examined, including two in clinical remission. It also assessed the effectiveness of protocols designed to purge malignant cells from marrow. Moreover, this approach enabled the rapid DNA sequencing of chromosomal breakpoints without their molecular cloning. This assay markedly refines the capacity to detect minimal residual disease and should improve the ability to determine the stage of disease, stratify treatment, and evaluate therapy.
Specific interchromosomal translocations occur in many types of neoplasms but are not found in their normal cellular counterparts (1) (2) (3) . The most frequent translocation in human lymphoma is the t(14;18)(q32;q21), which is detected by cytogenetics in approximately 85% offollicular small cleaved cell lymphomas (2, 4) . Moreover, a number ofcytogenetically indeterminant B-cell lymphomas, approximately 20o of diffuse large cell lymphomas, and 50%o of adult undifferentiated lymphomas possess the t(14;18), as determined by gene rearrangement analysis (5) .
Despite the mature B-cell phenotype of these lymphomas, the t(14;18) occurs at a very early stage of pre-B-cell development, when rearrangement of diversity (DH) and joining (JH) immunoglobulin heavy chain genes occurs (6) . This translocation juxtaposes a putative oncogene, BCL2, from 18q21 with an immunoglobulin JH segment on the derivative (der)14 chromosome (7) (8) (9) . This results in a BCL2-immunoglobulin fusion gene, chimeric transcripts, and a marked transcriptional deregulation of the translocated BCL2 (10) (11) (12) . The breakpoints are remarkably focused on chromosome segment 18q21, where 70% lie within a 2.8-kilobase (kb) major breakpoint region (MBR) and most cluster within a 150-base-pair (bp) area (6) . Thus, a translocation specific rearrangement unique to the neoplastic cells can be identified on Southern blots. This molecular marker can be used to follow the natural history of lymphomas (13) and search for minimal residual disease (MRD).
The rearrangement patterns of immunoglobulin and T-cell receptor genes in tumors have previously been used to identify residual or recurrent disease not detected by routine diagnostic studies (14) (15) (16) . However, such Southern blot examinations are relatively insensitive, detecting clonal cells only if they make up 1-5% of the total. Approaches to magnify these antigen receptor rearrangements are frustrated by their heterogeneous nature [alternative variable (V), D, and J segments] and their occurrence in normal as well as neoplastic cells. In contrast, the t(14;18) is an attractive tumor-specific marker with focused breakpoints on both chromosomes. We and Lee et al. (17) exploited this event to amplify the site of chromosomal juncture by DNA polymerase chain reaction (PCR). We utilized Thermus aquaticus (Taq) DNA polymerase (18) hybridized with random primed genomic or T4 polynucleotide kinase end-labeled oligonucleotide probes. PCR with the Klenow fragment of Escherichia coli DNA polymerase ("Klenow PCR") was performed with 370C annealing and synthesis as previously described (19) .
Direct DNA Sequencing of PCR Products. Predicted size fragments from PCR were identified by ethidium bromide staining, eluted from polyacrylamide, purified by C18 SepPak, precipitated, and quantitated. Then 120 ng of fragment was subjected to dideoxy chain termination sequence analysis using end-labeled oligonucleotide primers. Samples were subjected to two cycles of denaturation, annealing, and extension at 420C (20) . All dNTPs were at a final concentration of 0.16 mM; 2',3'-dideoxynucleotides ddGTP, ddATP, and ddTTP were 1 mM; ddGTP was 0.33 mM.
RESULTS
Klenow Amplification of the SU-DHL-6 Breakpoint by Using an Oligonucleotide 5' to the BCL2 MBR and 3' to JH6* We prepared a 20-residue oligonucleotide of the sequence found immediately 5' to the 150-bp cluster area within the BCL2 MBR (PCR-Oligo-1, 5'-TTAGAGAGTTGCTTTlACGTG-3') and a reverse complementary oligonucleotide specific for the 3' flanking segment of the JH6 region (PCR-Oligo-2, 5'-TAGAGTGGCCATTCTTACCT-3'). The der(14) breakpoint in the SU-DHL-6 cell line was at JH6, possessed 11 extra base pairs at the site of juncture (N segment), and measured 238 bp between PCR-Oligo-1 and -2. A 25-cycle PCR was performed on genomic DNA that was denatured at 950C, annealed to oligonucleotides at 370C, and synthesized with 1 unit of the Klenow fragment of DNA polymerase I per cycle. The presence of SU-DHL-6 DNA resulted in the amplification of a predicted 238-bp fragment hybridizing to both JH and BCL2 MBR probes (Fig. 1) . No hybridizable product was seen in cell line U937, which lacks the translocation. Serial dilution of SU-DHL-6 DNA to 10-5 with U937 DNA indi-G9 S [Vs Ji .iT [VS J2 ip. GT 
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Proc. Natl. Acad. Sci. USA 85 (1988) cated that only 10 pg of translocated DNA was needed for amplification ( Fig. 1) .
A Universal JH Primer and Taq DNA Polymerase. The der(14) juncture of the t(14;18) can involve any of the six JH regions. A universal JH primer would make it possible to amplify t(14;18) breakpoints without predetermining the JH segment utilized. The 3' portion of each JH segment is composed of a donor splice site and the highly conserved framework 4 region (21) . This enabled the construction of a 24-mer, PCR-Oligo-4, that was identical to three JH segments and differed by only 1-3 bp from the others (Fig. 2) . However, when PCR-Oligo-4 was used in the 370C Klenow PCR, a nontranslocated product from the germ-line 18q21 segment was also amplified. At 370C many partially identical sites within the 3 x 109 bp of the human genome also hybridize to such primers (as distant as 10 out of 19 nucleotides, in our experience). Those nonspecific products of JH or BCL2 origin also hybridized to the probes. To improve the specificity of primer base pair formation and remove the sink ofpartially identical sites, we use the DNA polymerase ofthe thermophilic microorganism Thermus aquaticus. This enabled the annealing step to be titrated to the highest optimal temperature for each oligonucleotide (Fig. 3) . Moreover, in a 45-cycle amplification, Taq polymerase needs to be added only at the beginning. Fig. 4 displays the ethidium bromidestained polyacrylamide gel of Taq PCR products and indicates that an ideal annealing temperature must be determined for each oligonucleotide selection. The number of partially identical sites amplified from the genome is markedly reduced with PCR-Oligo-1 and -4 by changing the annealing temperature from 51'C to 61TC. In addition, the amount of the specific breakpoint fragment synthesized is increased. When the oligomers are shortened to 15-mers, PCR-Oligo-ls, and -4s, virtually all of the nonspecific bands disappear at 61TC. However, 61°C is very near the functional melting point of these 15-mers and the sensitivity is reduced (Fig. 4) .
Direct Sequencing of Taq PCR-Amplifled Chromosomal Junctures. Hybridization of a genomic BCL2 MBR probe as well as an oligonucleotide probe representing sequence internal to the primers (Fig. 3 (Fig. 5) . The universal JH primer proved capable of amplifying der (14) breakpoints that used different JH regions (Fig. 6 ). The capacity of this technique to amplify a previously uncharacterized t (14;18) breakpoint was unequivocally demonstrated by gel purifying PCR-amplified breakpoint products and directly sequencing the fragments by dideoxy termination (Fig. 7) . A JH2 juncture with a 3-bp N segment and a classic BCL2 MBR recombination is shown. Moreover, Taq polymerase amplification products produced a valid sequence when breakpoints that had been previously cloned and sequenced were reexamined by this approach (not shown). Identification of MRD by Taq PCR. The sensitivity and specificity of the Taq PCR prompted a search for MRD in patients with follicular lymphoma (Fig. 8A) . All patients examined to date with amplifiable breakpoints in DNA of their diagnostic lymph node cells had PCR evidence of clonal cells in peripheral blood. Several patients had enough clonal cells to be detected by routine genomic blots, whereas patient 3's subclinical leukemia was detectable only by PCR. Patients 5 and 6 were felt to be in complete remission after chemotherapy when examined, but PCR demonstrated clonal cells in their peripheral blood (Fig. 8A) of lymphoma cells was reduced by treating the marrow with methyl prednisolone or etoposide and most markedly with the drugs in combination (Fig. 8B) PCR amplification should be applicable to other translocations, provided their DNA breakpoints are clustered so that limited numbers of oligonucleotides can be universally applied. Moreover, it should also be possible to amplify hybrid RNA transcripts such as the BCR-Abl products of chronic myelogenous leukemia (23) by converting mRNA to a DNA template with reverse transcriptase and then proceeding with the PCR. These approaches promise to improve our understanding of the biology of neoplasia and our ability to monitor it.
